HUTCHMED Fanregratinib Phase II Results
Analysis based on 6 articles · First reported Jun 24, 2026 · Last updated Jun 25, 2026
The positive clinical trial results for fanregratinib are expected to positively impact HUTCHMED's stock price due to the potential for future regulatory approval and commercialization. The priority review granted by the China — National Medical Products Administration suggests an accelerated path to market in China, which could further boost investor confidence in HUTCHMED.
HUTCHMED announced positive results from its pivotal Phase II registration study of fanregratinib (HMPL-453) for patients with intrahepatic cholangiocarcinoma (ICC). The study, conducted across 53 sites in China, met its primary endpoint with an objective response rate of 42.5%. Key secondary endpoints also showed consistent clinical activity and a manageable safety profile. The China — National Medical Products Administration accepted a New Drug Application for fanregratinib in December 2025 and granted it priority review. These results will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress in Munich, Germany, from July 1 to 4, 2026. Professor Jianming Xu of the General Hospital, the lead investigator, highlighted the therapeutic value of fanregratinib as a new treatment option for pretreated advanced ICC patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard